Commentary On Opaleye Management Positions, Part I [Seeking Alpha]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Seeking Alpha
Summary In this series we continue to comment on holdings of key hedge funds we follow, hoping to come away with an enhanced understanding of how the smart money thinks and a few ideas worthy of further research. In my most recent entries (see Part 1 and Part 2 ), we checked out some of the holdings of Great Point Partners, a noteworthy long/short healthcare focused fund known for deep fundamental analysis and their uncanny ability to uncover asymmetric risk/reward opportunities. Now we turn to James Silverman's Opaleye Management, a smaller more nimble fund with around $200 million of assets under management. With considerably less personnel than Great Point Partners (only 3 employees), Mr. Silverman has been running things since 1996. Late last year he made waves with very strong third quarter returns in excess of 38%. Today in part 1 we will evaluate a few of the fund's heaviest weighted positions that I find most intriguing. Stock #1: Blueprint Medicines ( B
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Kate Haviland [CNBC]CNBC
- Blueprint Medicines Co. (NASDAQ: BPMC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $97.00 price target on the stock.MarketBeat
- Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting [Yahoo! Finance]Yahoo! Finance
BPMC
Earnings
- 2/15/24 - Beat
BPMC
Sec Filings
- 3/26/24 - Form 4
- 3/22/24 - Form 4
- 3/19/24 - Form 4
- BPMC's page on the SEC website